# SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Source: https://onco.cc/trials/nct05642780/  
OnCo record `nct05642780` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab in advanced solid tumours, run by Klus Pharma Inc., active and no longer recruiting.

## Summary

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors is a phase 2 interventional study registered as NCT05642780 by Klus Pharma Inc., with 240 participants enrolled, started 2023-01-17 and due to reach its primary completion in 2027-11-30. Interventions recorded: SKB264 and Pembrolizumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05642780
- Phase: 2
- Setting: A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
- Sponsor: Klus Pharma Inc.
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT05642780: https://clinicaltrials.gov/study/NCT05642780

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Clario](https://onco.cc/companies/clario/), [Discovery Life Sciences](https://onco.cc/companies/discovery-life-sciences/), [Myriad Genetics](https://onco.cc/companies/myriad-genetics/), [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct05642780.json